布地格福吸入气雾剂对慢性阻塞性肺疾病患者炎症反应及肺通气功能的影响研究

Study on the Influence of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol on Inflammatory Response and Pulmonary Ventilation Function of Patients with Chronic Obstructive Pulmonary Disease

目的:探究布地格福吸入气雾剂对慢性阻塞性肺疾病患者炎症反应及肺通气功能的影响。方法:将2022年6月—2023年6月南昌市第三医院的120例慢性阻塞性肺疾病患者根据随机数字表法分为对照组60例和观察组60例。对照组采用布地奈德福莫特罗粉吸入剂进行治疗,观察组则采用布地格福吸入气雾剂进行治疗。比较两组的慢性阻塞性肺疾病治疗总有效率、不良反应发生率、治疗前后的炎症反应项目[血清及痰液白介素-8(IL-8)及白介素-17(IL-17)]及肺通气功能[残气量(RV)、残气量/肺总量(RV/TLC)及第1秒用力呼气容积占预计值百分比(FEV_(1)%pred)]。结果:观察组的慢性阻塞性肺疾病治疗总有效率显著高于对照组,不良反应总发生率显著低于对照组,差异均有统计学意义(P<0.05),治疗前两组的炎症反应项目及肺通气功能比较,差异均无统计学意义(P>0.05),治疗6周及12周后观察组的炎症反应项目及RV、RV/TLC均显著低于对照组,FEV_(1)%pred则均显著高于对照组,差异均有统计学意义(P<0.05)。结论:布地格福吸入气雾剂在慢性阻塞性肺疾病患者中的应用效果较好,且可显著改善患者的炎症反应及肺通气功能,因此在慢性阻塞性肺疾病患者中的应用价值较高。

Objective:To investigate the influence of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol on inflammatory response and pulmonary ventilation function of patients with chronic obstructive pulmonary disease.Method:A total of 120 patients with chronic obstructive pulmonary disease in Nanchang Third Hospital from June 2022 to June 2023 were divided into control group 60 cases and observation group 60 cases by the method of random number table.The control group was treated with Budesonide and Formoterol Fumarate Powder for Inhalation,the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.Then the total effective rates of chronic obstructive pulmonary disease treatment,adverse reactions rates,inflammatory response items[serum and sputum interleukin-8(IL-8)and interleukin-17(IL-17)]and pulmonary ventilation function[residual volume(RV),residual volume/total lung capacity(RV/TLC)and forced expiratory volume in one second as a percentage of expected value(FEV_(1)%pred)]before and after the treatment of two groups were compared.Result:The total effective rate of chronic obstructive pulmonary disease treatment of observation group was significantly higher than that of control group,the total adverse reactions rate was significantly lower than that of control group,the differences were statistically significant(P<0.05),the inflammatory response items and pulmonary ventilation function of two groups before the treatment were compared,the differences were not statistically significant(P>0.05),the inflammatory response items and RV,RV/TLC of observation group at 6th and 12th week after the treatment were significantly lower than those of control group,the FEV_(1)%pred were significantly higher than those of control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in the treatment of patients with chronic obstructive pulmonary disease is better,and it can significantly improve the inflammatory response and pulmonary ventilation function of patients,so its application value in patients with chronic obstructive pulmonary disease is higher.